Dear Editor, We read with great interest the pivotal report on dual immune checkpoint blockade (anti–PD-1/PD-L1 plus anti–CTLA-4) in advanced malignancies, which highlighted the clinical activity of combination immunotherapy in a large cohort (1). While combination regimens can provide meaningful efficacy outcomes, the toxicity burden remains a defining limitation. In the referenced trial, high-grade immune-related adverse events (irAEs), frequent treatment interruptions, and a non-negligible risk of fatal toxicity were notable alongside the efficacy signals (2). Current toxicity management frameworks in major guidelines (including NCCN and ESMO) provide comprehensive algorithms for irAE recognition and treatment; however, these recommendations have largely been shaped by monotherapy experience and selected trial populations (3). In routine practice, clinicians increasingly observe that combination regimens may generate earlier onset, higher severity, and more complex multisystem irAEs than those anticipated from guideline-based expectations derived predominantly from single-agent paradigms (4). Importantly, pharmacovigilance data reinforce this concern. Analyses of spontaneous reporting systems (e.g., FAERS, VigiBase, and JADER/PMDA) consistently demonstrate disproportionately higher reporting of severe irAEs with combination ICI regimens compared with monotherapy, supporting a signal of increased real-world toxicity burden (5-7). These findings should be interpreted as reporting/association signals (disproportionality) rather than incidence estimates; nevertheless, their concordance across databases suggests that the real-world safety profile of combination ICIs warrants heightened attention. Clinical Significance and Current Evidence Recent real-world and pharmacovigilance analyses have reported an increased likelihood of severe irAE reporting with combination regimens relative to single-agent therapy, including signals for organ-specific toxicities such as hepatitis, colitis, pneumonitis, and myocarditis (8-11). Likewise, meta-analytic evidence indicates that combination immunotherapy yields higher overall irAE rates than monotherapy across multiple settings; for example, in metastatic melanoma, overall irAE frequency has been reported as higher with combination therapy compared with single-agent ICI (12). Collectively, these data suggest that rare but potentially fatal toxicities—particularly myocarditis and severe neurologic syndromes—may occur at clinically meaningful rates and require proactive mitigation strategies (13). From a practical standpoint, irAEs under combination regimens often show earlier presentation, higher-grade severity, and greater need for immunosuppressive escalation, including steroid-refractory cases requiring second-line agents (e.g., infliximab, mycophenolate mofetil, vedolizumab, or other targeted immunosuppression) (14). Recent real-world cohort reports further indicate that hepatotoxicity, colitis, endocrine toxicities, pulmonary toxicity, and cardiotoxicity remain among the most clinically consequential events, frequently driving dose delays, prolonged immunosuppression, and permanent discontinuation (15). The burden is particularly pronounced in older patients and those with poorer performance status or significant comorbidities, where severe toxicity risk appears elevated and outcomes can be compromised by treatment discontinuation and prolonged recovery (16). Conclusions and Recommendations Taken together, contemporary evidence suggests that the toxicity profile of combination ICI regimens may exceed what clinicians expect when extrapolating from monotherapy-based guideline paradigms. We believe several practical steps could improve safety: Early recognition and intensified monitoring during the initial treatment period (when severe irAEs often emerge) (13). Structured, multidisciplinary toxicity pathways (oncology, gastroenterology, pulmonology, cardiology, endocrinology, rheumatology) to shorten time-to-treatment for severe irAEs (3). Risk-adapted patient selection incorporating age, performance status, comorbidity burden, prior autoimmunity, and organ reserve, with explicit counseling on discontinuation risk (17). Guideline refinements that clearly distinguish combination-regimen toxicity phenotypes from monotherapy and integrate high-quality real-world safety signals (pharmacovigilance + prospective observational cohorts). We respectfully suggest that future guideline updates include a dedicated section on combination ICI-specific toxicity patterns, emphasizing early severe irAE recognition, escalation strategies for steroid-refractory events, and risk stratification in vulnerable subgroups. Sincerely